Literature DB >> 15272111

Influences of distress and alcohol consumption on the development of a delayed-type hypersensitivity skin test response.

Alison J Smith1, Ute Vollmer-Conna, Barbara Bennett, Ian B Hickie, Andrew R Lloyd.   

Abstract

OBJECTIVE: This paper reports the effects of naturally occurring levels of distress on the development of delayed-type hypersensitivity (DTH) skin test responses. These in vivo measures provide a biologically relevant assessment of cellular immune competence.
METHODS: Subjects (N = 166) were immunized (baseline) with the novel antigen, keyhole limpet hemocyanin (KLH), and DTH skin test responses against KLH were assessed 3 weeks later (follow-up). The CMI Multitest (Merieux, France), which evaluates DTH responses to a panel of seven antigens, was also administered at follow-up. Emotional distress was assessed at baseline and follow-up by the Profile of Mood States.
RESULTS: Distress levels at baseline were associated with a reduced likelihood of developing DTH responses against KLH at follow-up (r = -0.22, p =.01). There was no relationship between distress at follow-up and cutaneous DTH in response to KLH (r = 0.09, p =.24) or in the Multitest (r = -0.03, p =.70). In addition, higher levels of alcohol consumption at baseline (r = -0.19, p =.02) and at follow-up (r = -0.20, p =.01) were associated with a decreased likelihood of developing cutaneous DTH against KLH.
CONCLUSIONS: Everyday levels of distress predicted the capacity of the cellular arm of the immune system to exhibit recall responses to an antigen, when the experimental paradigm allowed the assessment of distress at the time of antigen sensitization. Moderate alcohol consumption independently affected cutaneous DTH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272111     DOI: 10.1097/01.psy.0000130962.28801.af

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  7 in total

Review 1.  Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies.

Authors:  Ashwin Swaminathan; Robyn M Lucas; Keith Dear; Anthony J McMichael
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

2.  A corticoid-sensitive cytokine release assay for monitoring stress-mediated immune modulation.

Authors:  M Feuerecker; W Mayer; I Kaufmann; M Gruber; F Muckenthaler; B Yi; A P Salam; J Briegel; G Schelling; M Thiel; A Choukèr
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

Review 3.  Impact of Alcohol Abuse on the Adaptive Immune System.

Authors:  Sumana Pasala; Tasha Barr; Ilhem Messaoudi
Journal:  Alcohol Res       Date:  2015

4.  Regional differences in cell-mediated immunity in people with diabetic peripheral neuropathy.

Authors:  K Pickwell; M Geerts; D van Moorsel; D Hilkman; M Kars; N C Schaper
Journal:  Diabet Med       Date:  2019-10-10       Impact factor: 4.359

5.  OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.

Authors:  Mahdi Saghari; Pim Gal; Sally Gilbert; Martin Yateman; Ben Porter-Brown; Nuala Brennan; Sonia Quaratino; Rosamund Wilson; Hendrika W Grievink; Erica S Klaassen; Kirsten R Bergmann; Jacobus Burggraaf; Martijn B A van Doorn; John Powell; Matthijs Moerland; Robert Rissmann
Journal:  Clin Pharmacol Ther       Date:  2022-03-01       Impact factor: 6.903

6.  The health and well-being of Australia's future medical doctors: protocol for a 5-year observational cohort study of medical trainees.

Authors:  Erin Cvejic; Gordon Parker; Samuel B Harvey; Zachery Steel; Dusan Hadzi-Pavlovic; Claire L Macnamara; Uté Vollmer-Conna
Journal:  BMJ Open       Date:  2017-09-11       Impact factor: 2.692

7.  A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man.

Authors:  Mahdi Saghari; Pim Gal; Dimitrios Ziagkos; Jacobus Burggraaf; John F Powell; Nuala Brennan; Robert Rissmann; Martijn B A van Doorn; Matthijs Moerland
Journal:  Br J Clin Pharmacol       Date:  2020-10-28       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.